Global Chronic Myelogenous Leukemia Therapeutics Market to Grow by $2.14 Billion During 2022-2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Chronic Myelogenous Leukemia Therapeutics Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

The chronic myelogenous leukemia therapeutics market is poised to grow by $2.14 bn during 2022-2026, accelerating at a CAGR of 6.1% during the forecast period. The report on the chronic myelogenous leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strategic alliances.

The chronic myelogenous leukemia therapeutics market analysis includes the product segment and geographic landscape.

The chronic myelogenous leukemia therapeutics market is segmented as below:By Product

• Targeted therapy
• Chemotherapy
• Immunotherapy

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the emergence of pipeline molecules as one of the prime reasons driving the chronic myelogenous leukemia therapeutics market growth during the next few years. Also, the development of diagnostic tests and predictive markers and increasing research in regenerative medicines will lead to sizable demand in the market.

The report on the chronic myelogenous leukemia therapeutics market covers the following areas:

• Chronic myelogenous leukemia therapeutics market sizing
• Chronic myelogenous leukemia therapeutics market forecast
• Chronic myelogenous leukemia therapeutics market industry analysis

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Product

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

Companies Mentioned

• Amneal Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• C. H. Boehringer Sohn AG and Co. KG
• Dr Reddys Laboratories Ltd
• F. Hoffmann La Roche Ltd.
• Ilyang Pharmaceutical Co. Ltd.
• Innovent Biologics Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sheba Medical Center
• Sun Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Lupin Ltd
• Otsuka Holdings Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/m6r059

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900